Nose-to-brain drug delivery for the treatment of Alzheimer's disease: current advancements and challenges.
Prabakaran AMukta AgrawalMithun Rajendra DetheHafiz AhmedAwesh YadavUmesh GuptaAmit AlexanderPublished in: Expert opinion on drug delivery (2022)
The available therapies are symptomatic and mitigate the symptoms of AD at the initial stages. In lieu of this, nose-to-brain delivery has the ability to overcome these limitations and increase drug bioavailability in the brain. Various novel strategies including stimuli-responsive systems, nanoparticles, etc. enhance the nasal permeation, protect the drug, and enhance its therapeutic potency. However, successful preclinical data do not assure the clinical success of the therapy, and hence exhaustive clinical investigations are needed to make the therapy available for patients.
Keyphrases
- resting state
- white matter
- drug delivery
- end stage renal disease
- functional connectivity
- chronic kidney disease
- ejection fraction
- cancer therapy
- cerebral ischemia
- peritoneal dialysis
- stem cells
- multiple sclerosis
- emergency department
- big data
- adverse drug
- brain injury
- bone marrow
- replacement therapy
- patient reported outcomes
- combination therapy
- mesenchymal stem cells
- mild cognitive impairment